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Abstract
Introduction
Urine neutrophil gelatinase-associated lipocalin (uNGAL) is a sensitive and specific diag-
nostic test for acute kidney injury (AKI) in the Emergency Department (ED), but its economic
impact has not been investigated. We hypothesized that uNGAL used in combination with
serum creatinine (sCr) would reduce costs in the management of AKI in patients presenting
to the ED in comparison to using sCr alone.
Materials and methods
A cost simulation model was developed for clinical algorithms to diagnose AKI based on sCr
alone vs. uNGAL plus sCr (uNGAL+sCr). A cost minimization analysis was performed to
determine total expected costs for patients with AKI. uNGAL test characteristics were vali-
dated with eight-hundred forty-nine patients with sCr1.5 from a completed study of 1635
patients recruited from EDs at two U.S. hospitals from 2007–8. Biomarker test, AKI work-up,
and diagnostic imaging costs were incorporated.
Results
For a hypothetical cohort of 10,000 patients, the model predicted that the expected costs
were $900 per patient (pp) in the sCr arm and $950 in the uNGAL+sCr arm. uNGAL+sCr
resulted in 1,578 fewer patients with delayed diagnosis and treatment than sCr alone (2,013
vs. 436 pts) at center 1 and 1,973 fewer patients with delayed diagnosis and treatment than
sCr alone at center 2 (2,227 vs. 254 patients). Although initial evaluation costs at each cen-
ter were $50 pp higher in with uNGAL+sCr, total costs declined by $408 pp at Center 1 and
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by $522 pp at Center 2 due to expected reduced delays in diagnosis and treatment. Sensitiv-
ity analyses confirmed savings with uNGAL + sCr for a range of cost inputs.
Discussion
Using uNGAL with sCr as a clinical diagnostic test for AKI may improve patient management
and reduce expected costs. Any cost savings would likely result from avoiding delays in
diagnosis and treatment and from avoidance of unnecessary testing in patients given a false
positive AKI diagnosis by use of sCr alone.
Introduction
AKI has been associated with significantly increased health care costs. Data from 23 Massachu-
setts hospitals over 2 years demonstrated that AKI resulted in higher hospital resource utiliza-
tion, as both median direct hospital costs and hospital length of stay were increased by $2,600
and by 5 days, respectively, in patients with AKI vs. patients without AKI.[1] Furthermore,
Chertow et al. demonstrated that even uncomplicated AKI was associated both with greater
hospital costs and longer lengths of stay.[2] In the current and future eras of limited healthcare
budgets, it is critically relevant to evaluate the potential costs and economic impact of novel
diagnostic tests.
Measurement of urinary neutrophil gelatinase-associated lipocalin (uNGAL) has been dem-
onstrated to be an early, non-invasive marker of AKI due to a variety of etiologies, such as car-
diac surgery[3], intravenous contrast administration[4], critical care settings[5], and kidney
transplantation[6]. NGAL is the most studied marker of AKI and was demonstrated to be sen-
sitive and specific in the detection of AKI in the ED and for the prediction of a composite clini-
cal outcome of death and dialysis after in-patient admission [7, 8]. It is the most prominently
studied because i) it has an enormous dynamic range ii) responds in a dose-dependent fashion
to injury iii) responds within 3 hours of injury, which is important in emergency rooms iv)
responds to a wide range of injuries v) is easy to measure vi) due to the recent availability of
clinical platforms including a new NGAL dipstick vii) the test has been approved in Japan,
Korea, and parts of Europe. It is currently being reviewed by the FDA in the US. In comparing
a variety of potential biomarkers for study, the authors found NGAL tracks with significant
changes in levels of creatinine, and had a better AUC/ROC.[9] Thus, uNGAL values may then
be used to initiate AKI patient care algorithms earlier than sCr alone, and the application of
uNGAL to AKI diagnostics and management may potentially lead to improved patient
outcomes.
Although multiple investigations have demonstrated that uNGAL is a promising AKI bio-
marker with a potential application in the ED and other acute settings, little data exist regard-
ing its potential impact upon costs and resource utilization. Therefore it is at this time that a
cost analysis is particularly valuable at this time. Even though patients present to the ED with a
variety of conditions, which may or may not include AKI, our study chose to focus exclusively
on creatinine, the AKI diagnosis, and its cost implications. We therefore investigated the eco-
nomic impact of uNGAL measurement on AKI detection and management in patients pre-
senting to the ED with sCr levels 1.5 mg/dL. From a diagnostic perspective this level of sCr
is relatively non-specific as it may represent prerenal azotemia or stable CKD, in addition to
AKI. Moreover, a sCr above this cutoff, in the absence of baseline kidney function data, would
likely trigger clinicians to initiate an AKI clinical care pathway. We hypothesized that early
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and accurate AKI detection by uNGAL, in conjunction with sCr, would lead to more efficient
and less expensive patient care.
With limited clinical and economic data, the relationship between cost and efficacy of an
additional diagnostic biomarker becomes even more important for EDs when considering
adopting such a test. Given the lack of complete and perfect information, economic modeling
techniques are employed to determine cost-effectiveness. Such a model allows one to synthe-
size data from a variety of sources and estimate the clinical and cost outcomes on different
populations. Sensitivity analysis of the model allows one to verify the assumptions made in the
model and test the validity of uncertain data (including costs) usually obtained from a variety
of sources. Knowing the limitations of such modeling, we constructed a decision model to
compare the effectiveness of the addition of uNGAL to sCr versus sCr alone.
Materials and methods
A cost simulation model was developed (Microsoft Excel, Redmond, WA) for competing AKI
diagnostic strategies; 1) sCr alone; and. 2) uNGAL plus sCr (uNGAL+sCr). The model was
used to simulate a cohort of 10,000 adult patients with creatinine greater than or equal to 1.5
mg/dL from the period of presentation to the emergency department to hospital admission at
each hospital site in the United States. Costs were examined from the payer perspective.
Data for the model was obtained from the published literature. Additionally rates for out-
comes were obtained from a previous randomized controlled trial.[9] This dataset derived
from a broad and unbiased multicenter trial including a variety of races, locations, age, gender,
and socioeconomic statuses.[9] All comers consecutively to emergency rooms were included.
Inclusion criteria were broad and exclusion criteria were limited to appropriate groups for
consent purposes. ESRD was excluded as the authors wished to follow the reversibility of AKI.
Our present analysis derives from the review of this dataset. This study was approved by the
Institutional Review Board of Columbia University Medical Center and Staten Island Univer-
sity Hospital, and performed in compliance with HIPPA. Written, informed consent was
obtained from all participants.
Model structure
On the basis of the recommended clinical management of patients presenting to the ED with
AKI, the model was composed of two alternatives: sCr alone (Fig 1A) and sCr + NGAL (Fig
1B). This decision-tree was constructed based on previous literature [10, 11] and qualitative
analysis with expert opinion. The decision-tree framework provided the clinical testing
pathways.
For evaluation of sCr alone, patients with a level below the cutoff were not evaluated further
for kidney injury (Fig 1A). For uNGAL+sCr, four outcomes were possible (Fig 1B): (1) both
tests above cutoff levels; (2) sCr above cutoff level but uNGAL below cutoff level; (3) sCr below
cutoff level but uNGAL above cutoff level; and (4) both tests below cutoff levels. In case 1, all
patients were referred for further AKI testing. In case 4, no patients were referred for further
AKI testing. In case 2, patients were referred for further AKI testing unless they had known
stable chronic kidney disease (CKD) and in case 3, patients were referred for further AKI test-
ing unless they had evidence of urinary tract infection (UTI).
Input parameters
Data collected at NYP-Allen and SIUH provided the prevalence of both elevated sCr and
uNGAL, of UTIs, SIRS, and sepsis. For the baseline case, an elevated sCr level was assigned a
value1.75 mg/dL and an elevated uNGAL level was assigned a value 125 ng/dL. In both
NGAL reduces costs
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the sCr alone and uNGAL+sCr groups, a hypothetical cohort of 10,000 patients with suspected
AKI were evaluated and “run through” the model. Based on adjudication results of the study
completed at each site, we determined the prevalence of each condition. The prevalences
then allowed the calculations for the sensitivity and specificity in detecting AKI for sCr and
uNGAL.
Model assumptions
There are three sets of assumptions inherent to this analysis. The first set of assumptions is
dependent upon the false negative-AKI rate: (1) Patients in the ED with a sCr level below the
cutoff are sent home; (2) This results in a number of false negative-AKI diagnoses and a delay
in management; and (3) Those patients with a false-negative diagnosis based on sCr alone will
return to the ED, with a more severe disease state.
The second set of assumptions is dependent on the false positive-AKI rate: (1) Patients
assigned a false-positive AKI diagnosis were admitted to the hospital for an elevated sCr; (2)
A percentage of these hospital admissions were unnecessary (i.e. stable CKD, they could have
been discharged); and (3) Unnecessary testing was performed.
The third set of assumptions is dependent on the treating physician’s clinical approach:
(1) All patients in the ED with sCr above the cutoff level received AKI diagnostic testing;
(2) Additional testing was obtained in those patients admitted to the hospital. Clinical criteria
and results of these tests determined whether the patient had the systemic inflammatory
response syndrome (SIRS) or sepsis, and whether they would be admitted to the general wards
or the intensive care unit (ICU).
Patient population
Between January 1, 2007 and December 31, 2008, 1,120 consecutive patients were recruited
from the EDs at Staten Island University Hospital (SIUH) and the Allen Hospital of the New
York-Presbyterian Hospital (AH-NYPH) as part of a multicenter clinical study, which is
Fig 1. Simulation model. A cost simulation model was developed for competing testing strategies to evaluate for AKI; 1) Scr alone, vs. 2) uNGAL
plus Scr (uNGAL+Scr). Since the uNGAL+Scr treatment arm provided more diagnostic information, it was regarded as the “gold standard” relative to
Scr alone in terms of whether patients should be treated or whether treatment should be delayed.
https://doi.org/10.1371/journal.pone.0178091.g001
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detailed elsewhere.[12] Data regarding sCr values, clinical history and diagnostic tests were
collected. Due to poor specificity for discrimination of AKI, prerenal azotemia and stable CKD
at high levels of sCr, we restricted the cohort to only those patients having sCr levels 1.5 mg/
dL and from this used a sCr value of 1.75 as elevated. We hypothesized that above this
threshold, an AKI patient care algorithm, including serial sCr testing and renal ultrasound,
may likely be required to accurately discriminate AKI from other forms of kidney dysfunction
and that uNGAL testing could potentially provide useful diagnostic information regarding
kidney function for this set patients. This restriction left a sample of 476 patients as SIUH and
373 patients at AH-NYPH.
Patients18 years old in the ED, without a history of end stage renal disease (ESRD) and
without a need for renal replacement therapy, who were being admitted to the hospital were
enrolled from the ED at each site. One urine sample was collected and patient medical records
were accessed. Study team members were not in contact with treating physicians, except to
obtain permission to enroll patients.
Clinical efficacy and model outcomes
The primary clinical effect of the decision pathways was either hospital admission from the
emergency department or discharge to home. The model incorporated other clinical events
such as the recognition of a UTI, SIRS, or sepsis.
Costs
Data on hospital unit costs (e.g., daily costs for an inpatient stay) were obtained from Medicare
cost reports (Table 1). Baseline sCr cost was assumed to be $100 [13] with a range of $50-$200
if bundled with other tests. For uNGAL, baseline cost was $50, with a range of $25—$100 used
in sensitivity analysis [personal communication, Abbott Laboratories]. Other costs included
additional testing to identify AKI and possible complications (e.g. SIRS and sepsis).[14] Test-
ing to identify AKI included renal ultrasound, urinalysis, urine culture, and complete blood
cell count with differential. Additional testing to determine the presence of sepsis included
blood cultures. Total hospital and ICU length of stay were obtained from patients’ medical rec-
ords at each center. Hospital and ICU length of stay for patients with and without AKI were
compared and used to derive an incremental length of stay due to kidney disease. An estimate
for this incremental length of stay was varied throughout a wide range of values in the sensitiv-
ity analysis.
Sensitivity analysis
Due to uncertainty in the value of model inputs and the range of values and costs likely to be
captured in multiple different settings, sensitivity analyses were performed Table 1. Each cost
component was varied from one-half to twice its baseline value. A range for elevated sCr and
uNGAL values were also modeled in the sensitivity analysis: 1.5 to 2.0 for sCr and 100 to 150
for uNGAL. Ranges in the sensitivity analysis for the probability of elevated sCr and uNGAL
tests were based on their associated cutoff value ranges.
Results
Baseline demographics
476 patients at SIUH and 373 patients at AH-NYPH were adjudicated and used to construct
the model.
NGAL reduces costs
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Model results
The effects of sCr alone vs. uNGAL+sCr on expected treatment patterns are shown in Fig 2A
and 2B. Fig 2A compares the two treatment groups in terms of the expected number of
patients with delayed diagnosis and treatment. At both sites, the use of the uNGAL+sCr
reduced the expected number of patients with delayed diagnoses and treatment. For a hypo-
thetical cohort of 10,000 patients, using uNGAL+sCr would lead to 1,578 fewer patients with
diagnostic and treatment delays at the AH-NYPH, and 1,973 fewer patients with such delays at
SIUH. In contrast, Fig 2B reveals that uNGAL+sCr would also lead to more patients with
potential redundant/unnecessary treatment at both centers.
Fig 3A and 3B compare the two treatment arms in terms of cost per patient at the AH-
NYPH and at SIUH, respectively. At AH-NYPH, the use of uNGAL+sCr would lead to an
expected cost savings of $408 per patient on average, and to similar cost savings of $522 per
patient at SIUH. These savings were realized as a result of lower expected per patient hospitali-
zation costs (e.g. lower length of stay) and lower expected additional testing costs due to an
early and appropriate diagnosis.
Sensitivity analysis
The results of sensitivity analysis are shown in Fig 4A for AH-NYPH and in Fig 4B for SIUH.
The sensitivity analysis recalculates the net costs of sCr in comparison to uNGAL+sCr, varying
Table 1. Model input values for each site.
MODEL INPUT ALLEN SIUH SOURCE FOR BASELINE VALUES
Cohort Size 10,000 10,000 N/A
Scr Cost 100 (50–200) 100 (50–200) [13]
uNGAL Cost 50 (25–100) 50 (25–100) Abbott Laboratories
Cost of Further Testing 800 (400–1,600) 800 (400–1,600) [2, 13]
Cost of Test for SIRS 300 (150–600) 300 (150–600) [14]
Cost of Test for Sepsis 100 (50–200) 100 (50–200) [14]
Daily Hospital Cost 2,000 (1,000–4,000) 2,000 (1,000–4,000) [15]
Daily ICU Cost 6,000 (4,000–8,000) 6,000 (4,000–8,000) [15]
Average Incremental LOS in Hospital for Kidney Injury 2 (1–4) 2 (1–4) Derived from Dataset
Adjusted Average Incremental LOSa 1 (0.5–2) 1 (0.5–2) Derived from Dataset
Average Incremental LOS in ICU for Kidney Injury 3 (1.5–6.0) 3 (1.5–6.0) Derived from Dataset
Probability Scr Not Elevated 0.35(0.35–0.73) 0.29 (0.00–0.37) Dataset [9]
Probability uNGAL Not Elevated 0.63 (0.50–0.63) 0.62 (0.56–0.62) Dataset [9]
Percent True Positive Scr 0.34 (0.36–1.00)b 0.30 (0.34–1.00)b Dataset [9]
Percent True Negative Scr 0.86 (0.85–1.00) 0.93 (0.94–1.00)b Dataset [9]
Percent True Positive NGAL 0.52 (0.46–0.52) 0.40 (0.38–0.40) Dataset [9]
Percent True Negative NGAL 0.87 (0.85–0.88) 0.85 (0.85–0.86) Dataset [9]
Percent Patients with UTI 0.19 (0.10–0.38) 0.14 (0.07–0.28) Dataset [9]
Percent Patients with Stable CKD 0.22 (0.11–0.44) 0.38 (0.19–0.76) Dataset [9]
Percent Patients with SIRS 0.32 (0.16–0.64) 0.31 (0.16–0.62) Dataset [9]
Percent Patients with SIRS who become septic 0.06 (0.03–0.12) 0.01 (0.005–0.02) Dataset [9]
Data on hospital unit costs were obtained from Medicare cost reports. Each cost component was varied from one-half to twice its baseline value. A range for
elevated Scr and uNGAL values were also modeled in the sensitivity analysis: 1.5 to 2 mg/dL for Scr and 100 to 150 ng/mL for uNGAL.
a Adjusted average incremental costs pertain to patients who were admitted inappropriately—we assume that LOS is shorter for them.
b The baseline percent TP for Scr is based on the Scr> 1.75 criterion. For Scr> 1.5 and Scr >2 criteria, the percent TP for Scr were both greater than in the
baseline case. Similarly, the percent TN for Scr at the SIUH site was less in the baseline case (Scr>1.75) than in either the Scr>1.5 or Scr >2 scenarios.
https://doi.org/10.1371/journal.pone.0178091.t001
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Fig 2. Delayed treatment and redundant testing. At both sites, the use of the Scr+uNGAL would be expected to
reduce the number of patients with delayed diagnoses and treatment. For a hypothetical cohort of 10,000 patients,
the Scr+uNGAL strategy would lead to 1,578 fewer patients with diagnosis and treatment delays at the NYP-Allen,
and 1,973 fewer patients with such delays at SIUH. However, Scr+uNGAL could lead to redundant testing at both
centers. . . .
https://doi.org/10.1371/journal.pone.0178091.g002
NGAL reduces costs
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Fig 3. Effects on cost per patient. Effects on Cost Per Patient at NYP-Allen and SIUH. At NYP-Allen, the use
of uNGAL+Scr would lead to an expected cost savings of $408 per patient on average, and to similar cost
savings of $522 per patient at SIUH. These savings were reflected in lower per patient hospitalization costs and
lower additional testing costs.
https://doi.org/10.1371/journal.pone.0178091.g003
NGAL reduces costs
PLOS ONE | https://doi.org/10.1371/journal.pone.0178091 May 19, 2017 8 / 16
Fig 4. Sensitivity analysis. The sensitivity analysis recalculates the net expected cost of each strategy (Scr
vs. uNGAL+Scr), varying one model input at a time to its high and low values relative to its baseline value. At
both sites, costs of uNGAL+Scr remain lower for each scenario examined in the sensitivity analysis. At
NYP-Allen and SIUH, the results are most sensitive to hospital costs and length of stay, costs of additional
testing, and the percent of patients with CKD.
https://doi.org/10.1371/journal.pone.0178091.g004
NGAL reduces costs
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one variable in the model at a time. The value of a given variable is adjusted to high and low
values relative to its baseline value. At both sites, costs of uNGAL+sCr remained lower for
each scenario examined in the sensitivity analysis. At AY-NYPH and SIUH, the results are
most sensitive to hospital costs and length of stay, costs of additional testing, and the percent
of patients with CKD. The results of the complete sensitivity analysis are available in the
Appendix.
Discussion
In the past 15 years, renal diagnosis has been simplified by the use of the term acute kidney
injury (AKI). AKI severity can be stratified by either RIFLE, AKIN, or KDIGO criteria[16, 17];
higher AKI severity has been linked to poorer AKI-associated clinical outcomes.[18, 19] AKI
refers to 2 criteria: rise in serum creatinine and decrease in urine output. The current defini-
tion as per KDIGO criteria is independent of etiology or type of injury. This change in nomen-
clature has the benefit of homogenizing the approach to the patient; however, it does not
account for the fact of the different causes for the rise in creatinine have different treatments.
Elevated sCr due to CKD, prerenal azotemia, or medication administration have no distinction
from one another in KDIGO despite their drastically different clinical outcomes. Therefore, an
AKI biomarker with improved specificity could improve both stratification of AKI severity
and prediction of poor clinical outcomes. The NGAL gene and protein rise in the setting of
ischemic and inflammatory damage to the kidney, but do not become elevated in volume
depletion or related diseases like heart failure or liver failure. In the setting of AKI, uNGAL has
been demonstrated to rise 24–48 hours before sCr and to more accurately differentiate AKI
from prerenal azotemia.[20] Consequently, the fractionation of patients with elevated serum
creatinine levels into 2 different diagnostic categories (NGAL+/Cr+, NGAL-/Cr+) demon-
strates patients will respond to fluid therapy and those that will not.
Distinguishing various forms of AKI is a vexing problem. The time required for creatinine
to reach a meaningful threshold is indeterminate: milligram quantities of creatinine must
accumulate in the bloodstream from muscle. Consequently, the level of creatinine on presenta-
tion to the ED can never indicates the full extent of the defect in GFR for several days. sCr may
vary based upon age, gender, muscle mass, nutritional status, medication usage, hydration sta-
tus and existing co-morbid conditions.[21] For example, a patient with chronic kidney disease
(CKD) and a patient with AKI may present to the ED with a similar sCr. Therefore, accurate
identification of AKI in an acute ED setting based upon sCr is challenging. Because to date
AKI is defined by the level of creatinine, rather than biochemical outcomes and measures, con-
sequently it is difficult to define what clinical parameters constitute a false positive elevated
creatinine. As a result, creatinine is only useful as a retrospective biomarker of kidney function.
In contrast biomarkers, such as NGAL, respond immediately to an injurious stimulus: they
lack the delayed responses of serum creatinine. This is valuable for patients in the ED and tri-
age decision-making. The potential to identify AKI both early and more accurately would
greatly assist assignment of patients to proper levels of care and potentially improve clinical
outcomes. In other words, earlier detection of AKI may permit timely interventions that may
improve patient management and reduce costs.
The incidence of AKI in hospitalized patients ranges from 5–7% and is rising rapidly.[22–
25] In a multinational study published in 2005 of critically ill patients, the prevalence of AKI
requiring dialysis was 5.7% with a mortality rate of 60.3%.[26] From 2001 to 2011, data from
US centers suggest that while the prevalence of dialysis-requiring acute kidney injury has
increased, the mortality rate has decreased (from 28.0 to 19.7%).[27] In addition, patients with
AKI have a higher risk for developing other non-renal co-morbidities [28] and when present
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in conjunction with other conditions, AKI is associated with higher mortality.[2, 29, 30]
Although no treatment to reverse AKI exists, early detection assists pre-emptive assignment of
patients to higher levels of care. In JACC 2012, the authors found that Cr+/NGAL- or Cr-/
NGAL+ have a 5% chance of dialysis or death within 7 days.[9] In contrast, NGAL+/Cr+ had a
risk of 15% in 7 days. Nearly identical data were obtained when KIM-1 was studied.[9] Hence,
the authors demonstrated, the combination of biomarkers represents a higher risk state than
either alone. Indeed, the high morbidity and mortality of AKI in part reflects poor early detec-
tion due to the lack of an acute kidney injury biomarker and delay in placement to a higher
level of acuity care.
Our investigation suggests that when sCr is in a relatively non-specific range for the diagno-
sis of AKI, using a combination of uNGAL and sCr leads both to a clinical benefit and an eco-
nomic savings over sCr alone. The use of uNGAL in the ED leads to better triage decisions
and a $408 per patient and $522 per patient savings at NYP-Allen and SIUH, respectively.
Although in populations where sCr has high diagnostic accuracy for AKI the additional use of
uNGAL may not result in cost savings, it may lead to improved patient management and by
inference, better clinical outcomes. Our sensitivity analysis further shows that the superiority
of using uNGAL and sCr is contingent on the total hospital costs, length of stay, and costs of
additional testing when AKI is suspected. Additionally, the ability to identify patients with
CKD is another area where the addition of uNGAL is economically beneficial.
Despite growing evidence to support uNGAL as an AKI diagnostic test, there are no data
regarding its economic impact. Our investigation provides the first cost analysis of uNGAL
utilization in AKI detection. We developed a model that assumed that the “real world” clinical
implementation of uNGAL would be in conjunction with sCr. Patient data to support this
analysis was derived from patients who presented with suspected AKI to the EDs at two U.S.
medical centers located in New York City that serve two very different communities: one an
inner-city academic center and the other a community-based hospital. Although this model
suggests that the addition of uNGAL to sCr for AKI detection may lead to higher up-front
direct costs, these initial costs are offset by potential savings due to reductions in delayed diag-
nosis and treatment. These models demonstrate that uNGAL+sCr resulted in 1,578 and 1,973
fewer patients experiencing delayed diagnosis and treatment at Center 1 (AH-NYPH) and
Center 2 (SIUH), respectively. These findings are not surprising given the poor specificity of
sCr in the population of patients selected for this analysis.
Cost estimates in these analyses are likely “conservative.” We expect higher costs would
result from treatment delays due to delayed diagnosis, leading to greater illness severity, and
therefore poorer clinical outcome and higher levels of inpatient care.[31–34] Therefore, these
results suggest that cost savings achieved by adding uNGAL to sCr are proportional to avoid-
ing those additional costs incurred with delayed diagnosis. Treatment delays increase costs
because patients improperly diagnosed as being AKI-negative return for repeat testing in addi-
tion to eventual treatment and inpatient admission. Although treating patients unnecessarily
adds costs, we expect false positive diagnoses would have short hospital stays, mitigating cost
increases due to unnecessary treatment. Hence in this analysis, errors of commission (e.g.,
treating patients unnecessarily) are less costly then errors of omission (e.g., inappropriate diag-
noses and treatment delays). Likely patients will be admitted for other diagnoses for which for
the sake of simplicity our model does not account. However, early recognition of AKI will lead
to early treatment and lower costs.
This investigation has limitations. First, this is a simulation model rather than a prospective
investigation. Typical for these models, data must be collected from a variety of sources,
including published studies and cost reports; clinical judgment and assumptions are utilized in
cases where the former is unavailable. Model inputs may have varying accuracy or relevance in
NGAL reduces costs
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different medical settings. The model also assumes that patients, initially who were false-nega-
tives, on follow-up would be at the same AKI severity level as when they were initially evalu-
ated. However, we choose study sites serving different socioeconomic groups with different
prevalence rates of comorbidities in order to increase the generalizability of our models. Fur-
thermore, the results are robust in sensitivity analysis where the underlying variables are tested
throughout a wide range of values likely to be encountered in clinical practice; the cost advan-
tage of uNGAL+sCr persists over a wide range of costs and clinical values. For example,
although one source was used to estimate the cost of creatinine, multiple values were tested
through the sensitivity analysis. The savings benefit of uNGAL+sCr relies upon the total hospi-
tal costs, length of stay, the costs of additional testing when AKI is suspected, and the ability to
identify patients with CKD. Although these models do not account for acute dialysis, quality of
life, and mortality, we would expect these poor clinical outcomes to increase cost, in particular
for those patients inappropriately given a false negative AKI diagnosis.
This analysis of uNGAL as an AKI diagnostic test suggests that combining uNGAL with
sCr results both in clinical and cost benefits in specific settings. When sCr is in a non-specific
range for AKI detection, combining uNGAL with sCr may lead to earlier AKI detection and
treatment and avoidance of an inappropriate false negative diagnosis of AKI. Per patient sav-
ings ranged from $408—$522 at two separate centers. Longitudinal studies are necessary to
investigate the cost-effectiveness of uNGAL, used both with and without sCr, for the diagnosis
of AKI.
Appendix
Additional methods: Evaluations of diagnostic test characteristics and
assignment of gold standard test status
To evaluate each test’s diagnostic precision, we calculated their positive and negative predictive
values (PPV and NPV, respectively). For this investigation, we assigned ‘gold standard’ test sta-
tus to the uNGAL+sCr combination for both AKI detection and for decision to continue with
further testing or send home (i.e. delaying treatment) as the combination provided the greatest
amount of diagnostic information in comparison to either test alone. Therefore, delaying treat-
ment was decided to be unambiguously appropriate if both uNGAL and sCr, adjusted for their
false negative rate, were below pre-assigned cutoff levels. Comparisons were then made
between uNGAL+sCr and sCr alone groups for delayed treatment rates. A similar approach
was used to evaluate prevalence estimates of patients who were determined to have been
treated unnecessarily. To determine if further testing was unambiguously required, we used
the number of patients treated in the uNGAL+sCr arm, adjusted for the false positive rate,
yielding the number of patients who unambiguously required further treatment. This was then
compared to the number of patients treated in the sCr arm to determine how many patients
were treated unnecessarily in that arm. In addition, the following model assumptions were
made: 1) false negatives would become symptomatic for AKI and require further diagnostic
evaluation; and 2) false positives underwent further AKI diagnostic evaluation.
Finally, we estimated the joint sensitivity (PPV) and specificity (NPV) for uNGAL+sCr by
assuming the PPV and NPV of the combined measures were equivalent to the PPV of NPV of
the highest measure. Therefore, if the PPVs of uNGAL and sCr were 0.5 and 0.4, respectively,
the joint PPV was 0.5. This approach assumed that given the same PPV and NPV each test
would result in the same individuals considered as being either truly positive or negative. This
was done to provide the most conservative estimate of the joint probability. If we had assumed
the PPV and NPV of each diagnostic test was independent, then an additive model would be
required (e.g, 0.5 + 0.4 = 0.9), which might artificially inflate the joint probabilities. The
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decision trees describing the treatment patterns under sCr and uNGAL+sCr are shown in Fig
1A and 1B, respectively.
Assignment of kidney function diagnosis
Adjudications. The patients’ clinical course was evaluated by investigators blinded to bio-
marker data, who assigned adjudications and hence diagnosis (ES, PAC, KSO, TLN). Esti-
mated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal
Disease (MDRD) formula.[35] Patients were assigned to one of four diagnoses based upon
strictly defined criteria as detailed below15:
Normal kidney function: (1) Baseline eGFR>60 ml/min/1.73m2; (2) Failure to meet minimal
RIFLE criteria for AKI;[18] (3) no transient or sustained changes in sCr during the first
three days of hospitalization (0.3 mg/dl when baseline sCr was1.0 mg/dl, or0.2 mg/dl
when the baseline sCr was1 mg/dl); and (4) no recent exposures to AKI risk factors
(shock requiring vasopressors, positive blood cultures, SIRS or sepsis, nephrolithiasis,
recent chemotherapy, nephrotoxins, rhabdomyolysis, glomerulonephritis, acute interstitial
nephritis) or dialysis therapy.
Stable CKD: Identical characteristics as patients with normal kidney function but baseline
eGFR <60 ml/min/1.73m2 and stable >3 months prior to admission.
Prerenal Azotemia: Patients who met minimal RIFLE criteria for AKI (1.5-fold increase in
sCr or a 25% decrease in eGFR from baseline) at admission, but normalized their values
within three days after admission. Their historical and laboratory data suggested decreased
kidney perfusion, rather than exposure to AKI risk factors. They typically were treated with
measures to restore perfusion, such as fluids or discontinuation of diuretics.
AKI: These patients met minimal RIFLE criteria for AKI which failed to normalize within
three days following admission despite fluid therapy. Any patient who had a compelling
reason for AKI that occurred after urine sampling (for example a new radiocontrast study
or overdose with a nephrotoxin) was excluded.
sCr and uNGAL measures. Investigators assaying sCr and uNGAL were blinded to the
diagnostic adjudications (KF, MS). In addition uNGAL measurements were unavailable to
physicians who were responsible for the clinical management of the patients enrolled in this
investigation. uNGAL was considered elevated if its value exceeded 125 ng/dL and sCr was
considered elevated if its value exceeded 1.75 mg/dL. In a sensitivity analysis (detailed later),
alternative values of sCr were used to define lower bound estimates of elevated sCr (1.5 mg/
dL) and upper bound estimates of elevated sCr (> 2 mg/dL). Likewise, alternative values of
uNGAL were considered for lower bound (>100 ng/dL) and upper bound (> 150 ng/dL) esti-
mates of elevated uNGAL. Based on these cutoff values, the prevalence of patients with ele-
vated sCr and uNGAL values were obtained from the two sites.
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